Peptides for concussion FAQ

Administer nothing without medical clearance confirming intracranial bleeding has been ruled out via CT imaging. The neuroprotective window for compounds like Semax theoretically peaks within 6–12 hours post-injury based on rodent TBI models, but introducing exogenous signaling molecules before confirming structural brain integrity creates unquantifiable risk. Peptides that promote angiogenesis or modulate clotting cascades could theoretically worsen subdural or subarachnoid hemorrhage. Standard of care remains rest, cognitive load reduction, and serial symptom monitoring for the first 24–48 hours.

Ask three questions: which compounds in the stack have human trial data in TBI populations, what published dosing protocols are they following, and how are they monitoring outcomes beyond subjective symptom reporting. Most peptide stacks combine BPC-157, Semax, and Cerebrolysin or Thymalin. The evidence base for synergistic effects in combination is entirely theoretical. We've reviewed dozens of practitioner protocols; fewer than 15% cite peer-reviewed references for their specific dosing schedules.

You're operating outside regulatory oversight and assuming unknown risks. Peptides sourced from research suppliers like Real Peptides guarantee molecular purity and accurate amino-acid sequencing. But that's a quality assurance statement, not medical guidance. Self-administration without baseline cognitive testing (ImPACT, CNS Vital Signs) means you can't objectively measure whether the intervention produced improvement or whether natural recovery timelines account for perceived benefit. Subcutaneous peptide injection also carries infection risk if aseptic technique isn't maintained.

Lyophilised peptides should appear as white-to-off-white powder; any discoloration (yellow, brown) suggests oxidation or contamination. Reconstituted solutions should be clear and colorless. Cloudiness indicates protein aggregation that eliminates bioactivity. Temperature excursions above 8°C during shipping denature peptide structure irreversibly; visual inspection cannot detect this. Verify the supplier is an FDA-registered 503B facility or operates under equivalent regulatory oversight. Unregulated peptide sources lack batch testing for purity, potency, and endotoxin levels.

Consult a physician before administering any peptide. TBI requires medical evaluation to rule out intracranial bleeding, skull fracture, or evolving hematoma that peptides cannot address. Cerebrolysin shows efficacy when started within 24–48 hours post-injury in clinical trials, but IV administration requires clinical supervision. Subcutaneous peptides like P21 or Dihexa lack human TBI dosing data and should not replace standard concussion protocols (rest, cognitive restriction, gradual return-to-activity under medical oversight).

Chronic post-concussive symptoms (headaches, brain fog, mood changes persisting beyond 3 months) may respond to peptides targeting neuroinflammation or synaptic plasticity, though evidence is weaker than acute-phase interventions. P21's effects on long-term potentiation and dendritic spine density suggest potential for late-stage cognitive recovery, but no trials have tested this directly. Thymalin addresses prolonged microglial activation that contributes to persistent symptoms. Dosing follows the same 10mg daily protocol, though optimal treatment duration for chronic cases remains undefined.